Decreased Levels of Serum IGF-1 and Vitamin D Are Associated With Cognitive Impairment in Patients With Type 2 Diabetes. 2019

Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
Department of Endocrinology, Shanghai General Hospital of Nanjing Medical University, Nanjing, China.

To determine the association of serum insulin-like growth factor 1 (IGF-1) and vitamin D levels with cognition status in patients with type 2 diabetes mellitus (T2DM). A total of 173 patients with T2DM were recruited and divided into mild cognitive impairment (MCI) group (n = 94) and normal cognition (NC) group (n = 79). Levels of IGF-1 and 25(OH)D were measured and compared, and the correlations among IGF-1, 25(OH)D, and cognitive function were analyzed. Insulin-like growth factor 1 and 25(OH)D levels significantly decreased in MCI group than those in the NC group (both P < .001). Multiple stepwise regression analysis revealed that IGF-1 (β = .146, P < .001) and 25(OH)D (β = .199, P < .001) independently predicted Montreal Cognitive Assessment (MoCA) scores. Partial least square regression showed that contributions of both 25(OH)D (P < .001) and IGF-1 (P < .001) to MoCA scores were significant, while no cross-effect was observed between them (P = .714). Low serum IGF-1 and 25(OH)D levels may separately predict poor cognitive performance in patients with diabetes.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002112 Calcifediol The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. 25-Hydroxycholecalciferol,25-Hydroxyvitamin D 3,25-Hydroxycholecalciferol Monohydrate,25-Hydroxyvitamin D3,Calcidiol,Calcifediol Anhydrous,Calcifediol, (3 alpha,5Z,7E)-Isomer,Calcifediol, (3 beta,5E,7E)-Isomer,Calderol,Dedrogyl,Hidroferol,25 Hydroxycholecalciferol,25 Hydroxycholecalciferol Monohydrate,25 Hydroxyvitamin D 3,25 Hydroxyvitamin D3,Anhydrous, Calcifediol,Monohydrate, 25-Hydroxycholecalciferol
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D048909 Diabetes Complications Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Complications of Diabetes Mellitus,Diabetes-Related Complications,Diabetic Complications,Diabetes Complication,Diabetes Mellitus Complication,Diabetes Mellitus Complications,Diabetes Related Complications,Diabetes-Related Complication,Diabetic Complication
D060825 Cognitive Dysfunction Diminished or impaired mental and/or intellectual function. Cognitive Disorder,Mild Cognitive Impairment,Cognitive Decline,Cognitive Impairments,Mental Deterioration,Cognitive Declines,Cognitive Disorders,Cognitive Dysfunctions,Cognitive Impairment,Cognitive Impairment, Mild,Cognitive Impairments, Mild,Decline, Cognitive,Declines, Cognitive,Deterioration, Mental,Deteriorations, Mental,Disorder, Cognitive,Disorders, Cognitive,Dysfunction, Cognitive,Dysfunctions, Cognitive,Impairment, Cognitive,Impairment, Mild Cognitive,Impairments, Cognitive,Impairments, Mild Cognitive,Mental Deteriorations,Mild Cognitive Impairments

Related Publications

Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
September 2017, BMC infectious diseases,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
January 2019, Diabetes, metabolic syndrome and obesity : targets and therapy,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
October 2011, Diabetes,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
January 2023, Diabetes, metabolic syndrome and obesity : targets and therapy,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
January 2018, Journal of diabetes and its complications,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
March 2014, Endocrine,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
October 2013, Bone,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
November 2018, BMC endocrine disorders,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
May 2022, BMC endocrine disorders,
Chen Rui-Hua, and Peng Yong-de, and Jiang Xiao-Zhen, and Jason Chen, and Zhou Bin
November 2023, Multiple sclerosis and related disorders,
Copied contents to your clipboard!